Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
JUVÉDERM® Day Returns to U.S. on August 19
08:00am, Thursday, 30'th Jul 2026
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S
AbbVie Inc. $ABBV Position Increased by Arkadios Wealth Advisors
03:59am, Thursday, 30'th Jul 2026
Arkadios Wealth Advisors grew its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 5.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,885 shar
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
05:00pm, Wednesday, 29'th Jul 2026
But is that performance sustainable?
AbbVie successfully transitioned away from Humira over the past three years. It still looks cheap relative to its long-term growth potential.
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas
RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, wh
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
02:11pm, Tuesday, 28'th Jul 2026
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st
01:09pm, Tuesday, 28'th Jul 2026
AbbVie (NYSE:ABBV | ABBV Price Prediction) enters its July 31 Q2 earnings report with a 2.62% dividend yield, raised earnings guidance, and two blockbuster drugs growing above 20%.
Prediction: This ‘Boring’ Dividend ETF Secretly Rides the AI Trade and Out-Earns Your High-Yield Fund by 2036
11:55am, Tuesday, 28'th Jul 2026
DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over th
Should You Buy AbbVie Stock Hand Over Fist Before July 31?
06:45pm, Monday, 27'th Jul 2026
After reporting an earnings beat last quarter, AbbVie could once again beat expectations in the second quarter, although management recently warned about the negative impact of one-time charges. Share
Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck
11:40am, Monday, 27'th Jul 2026
The 2026 Social Security COLA came in at just 2.8%, which is barely keeping pace with a grocery bill, let alone replacing a paycheck.
Sarepta names former Abbvie president as CEO as Ingram retires
09:19am, Monday, 27'th Jul 2026
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Gabelli Funds LLC Sells 25,600 Shares of AbbVie Inc. $ABBV
03:55am, Monday, 27'th Jul 2026
Gabelli Funds LLC reduced its position in AbbVie Inc. (NYSE: ABBV) by 31.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 55,613 shares of the company's st
